Patients who are currently receiving other anticancer agents
Research participants receiving any other anticancer or investigational drug therapy
Patients receiving any other anticancer or investigational drug therapy
Patients who are actively receiving any other anticancer therapy except for hormonal therapy for well-controlled breast or prostate cancer
Patients receiving any other anticancer or experimental drug therapy
Patients who are receiving any other anticancer or investigational agents
Receiving any anticancer therapy for biliary tract cancer =<  days prior to registration
Participants who are currently receiving other anticancer agents.
Patients who are actively receiving any other anticancer therapy
Patients who are receiving any other anticancer agents.
Patients who are receiving any other anticancer therapy
Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy
Patient is receiving concomitant standard and/or investigational anticancer therapy; local palliative radiotherapy is permissible upon discussion with the principal investigator
Patients who are receiving any other anticancer or investigational drug therapy are not eligible
Patients receiving any other anticancer or experimental drug therapy
Anticancer Agents: participants who are currently receiving other anticancer agents
Not currently receiving any anticancer therapy
Subjects who are currently receiving any other concomitant anticancer therapy with the EXCEPTION of bisphosphonates and hormone therapy.
Patients who are currently receiving other anticancer agents are not eligible
Is receiving other concomitant anticancer treatment
Patients who are receiving any other anticancer therapy
Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivation
Subjects may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapy
Patients receiving any other anticancer or experimental drug therapy
Currently receiving anticancer therapy
Patients who are receiving any other investigational agents for anticancer treatment within  weeks of starting study medication
Currently receiving anticancer therapy or have received anticancer therapy within the past  days or  half-lives of the anticancer therapy
Concurrently receiving any other concomitant anticancer or experimental drug therapy
